Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Leases: 2021-2024

Historic Current Leases for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $1.2 million.

  • Krystal Biotech's Current Leases rose 31.42% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 31.42%. This contributed to the annual value of $1.2 million for FY2024, which is 17.44% down from last year.
  • Latest data reveals that Krystal Biotech reported Current Leases of $1.2 million as of FY2024, which was down 17.44% from $1.5 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Current Leases ranged from a high of $1.6 million in FY2022 and a low of $1.0 million during FY2021.
  • In the last 3 years, Krystal Biotech's Current Leases had a median value of $1.5 million in 2023 and averaged $1.4 million.
  • In the last 5 years, Krystal Biotech's Current Leases surged by 49.95% in 2022 and then declined by 17.44% in 2024.
  • Yearly analysis of 4 years shows Krystal Biotech's Current Leases stood at $1.0 million in 2021, then spiked by 49.95% to $1.6 million in 2022, then decreased by 5.57% to $1.5 million in 2023, then fell by 17.44% to $1.2 million in 2024.